Lymphoma
If it’s your first time on this website, please read the disclaimer section.
Oct 05 – Oct 12, 2026
Boosting CAR T cell efficacy in cancer with metabolic insights from design to diet.
NAT REV CANCER · Q1 JOURNAL - RANK #3/326TOP-TIER
This review explores how metabolic insights can boost CAR T cell efficacy in cancer, particularly for solid tumours. It examines the impact of CAR design, manufacturing platforms, and host metabolism on T cell fitness and antitumour activity. The abstract highlights that co-stimulatory domains induce distinct metabolic profiles and that manufacturing protocols lack standardization. It proposes leveraging diet-based interventions as a clinically accessible strategy to enhance CAR T cell therapy, aiming for more durable responses in cancer patients.
10.1038/s41568-026-00984-2
Sep 07 – Sep 14, 2026
LymphGen-Sig: Integrating Genetic and Transcriptional States to Predict Therapeutic Response in Diffuse Large B-Cell Lymphoma.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This study developed LymphGen-Sig (LGsig), a 294-gene expression-based platform designed to classify diffuse large B-cell lymphoma (DLBCL) by integrating genetic and transcriptional data from 764 patients. Validated using 678 samples from the POLARIX trial, LGsig successfully reclassified previously unassigned cases and TP53-altered tumors into biologically relevant clusters. The tool identified specific DLBCL subtypes that achieved superior survival outcomes with polatuzumab vedotin-R-CHP compared to standard R-CHOP therapy. By expanding molecular classification beyond traditional genetic markers, LGsig provides a robust framework for precision oncology and subtype-specific therapeutic decision-making in clinical practice.
10.1200/JCO-26-00451
Aug 24 – Aug 31, 2026
Generalised eruptive histiocytosis mimicking lymphoma relapse in a patient with previous diffuse large B-cell lymphoma.
LANCET · Q1 JOURNAL - RANK #1/332TOP-TIER
This case report describes a 92-year-old male with a history of diffuse large B-cell lymphoma who presented with new cutaneous nodules, initially raising suspicion for oncological relapse. Histopathological analysis revealed a non-Langerhans cell histiocytic infiltrate (CD68+, CD163+) and negative PET-CT imaging, ruling out malignancy and confirming generalized eruptive histiocytosis. The lesions spontaneously regressed within three months without intervention, and the patient remained disease-free at a 15-month follow-up. The study highlights the importance of broad differential diagnoses and biopsy confirmation in cancer survivors to distinguish benign mimics from true neoplastic recurrence.
10.1016/S0140-6736(26)01386-3
Cancer Biologics Utilization After Biosimilar Entry and Financial Implications For Payers and Patients.
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This retrospective cohort study assessed the market dynamics and financial implications of biosimilar entry for three anticancer biologics (bevacizumab, rituximab, trastuzumab) using commercial and Medicare data from 14,655 patients with breast, lymphoma, and colorectal cancers. Key findings revealed that biosimilar entry led to an average 3.8% annual decline in reference product average sales price and a 30-31.5% annual decrease in market share. Patients exclusively using biosimilars experienced a $3820 lower mean monthly payer cost and $39.50 lower mean monthly out-of-pocket cost compared to those using reference products. These results suggest that biosimilar competition in oncology reduces costs for both payers and cancer patients, potentially improving access and affordability of crucial cancer treatments.
10.1001/jamaoncol.2026.3128
Aug 10 – Aug 17, 2026
Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This phase 2 study evaluated a chemotherapy-free regimen using mosunetuzumab followed by response-adapted polatuzumab vedotin and obinutuzumab in 42 patients with untreated follicular or marginal zone lymphoma. Results demonstrated a 100% overall response rate and an 86% complete response rate, with mosunetuzumab monotherapy alone achieving a 71% complete response rate. At 34 months median follow-up, the 2-year progression-free survival was 89% and overall survival was 100%, with toxicity limited to grade 1 cytokine release syndrome. These findings suggest that this personalized, response-adapted approach provides high efficacy and a favorable safety profile for indolent B-cell lymphomas, potentially offering a viable alternative to traditional chemoimmunotherapy.
10.1200/JCO-25-02906
Aug 03 – Aug 10, 2026
Contemporary Management of Relapsed or Refractory Chronic Lymphocytic Leukemia.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This review examines contemporary management strategies for relapsed or refractory chronic lymphocytic leukemia (CLL/SLL) within the evolving landscape of targeted and cellular therapies. The analysis highlights that second-generation covalent BTK inhibitors and venetoclax-based regimens provide durable control, while noncovalent inhibitors like pirtobrutinib and CAR-T therapies like lisocabtagene maraleucel offer efficacy for heavily pretreated patients. Clinicians must integrate genomic re-evaluation, prior therapy response, and patient comorbidities to optimize the sequencing of emerging agents such as BTK degraders and bispecific antibodies. Individualized treatment planning and clinical trial participation remain essential to navigate increasing therapeutic complexity and improve outcomes for patients with double-class refractory disease.
10.1200/JCO-26-00428
Jul 20 – Jul 27, 2026
Ultralow-Dose Interleukin 10-Expressing Chimeric Antigen Receptor T Cells in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Nonrandomized Clinical Trial.
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This phase 1 clinical trial evaluated the safety and efficacy of ultralow-dose IL-10-expressing CAR T cells (META 10-19) in 13 patients with relapsed/refractory diffuse large B-cell lymphoma. Results demonstrated a high objective response rate of 92.3%, including an 84.6% complete remission rate, despite using significantly lower cell doses than standard protocols. Safety outcomes were manageable, with grade 3 cytokine release syndrome occurring in only one patient and low-grade neurotoxicity in two patients. These findings suggest that META 10-19 provides potent antitumor activity with a favorable safety profile, though further research is needed to address the 53.8% relapse rate observed during follow-up.
10.1001/jamaoncol.2026.2490
High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial.
LANCET · Q1 JOURNAL - RANK #1/332TOP-TIER
This phase 3 randomized trial compared high-dose chemotherapy with autologous stem-cell transplantation (HCT-ASCT) versus non-myeloablative R-DeVIC consolidation after MATRix induction in 229 newly diagnosed primary CNS lymphoma patients. After a median follow-up of 45.3 months, 3-year progression-free survival was significantly superior with HCT-ASCT at 78% (95% CI 69-85) compared to 51% (41-60) for R-DeVIC (HR 0.43; p=0.0003). While HCT-ASCT had more adverse events (mean 14.6 vs 9.3), it significantly improved progression-free and overall survival. This establishes HCT-ASCT as the preferred consolidation strategy for fit patients with primary CNS lymphoma, directly impacting clinical practice.
10.1016/S0140-6736(26)00917-7